You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Chartwell Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for CHARTWELL, and what generic and branded alternatives to CHARTWELL drugs are available?

CHARTWELL has five hundred and seventy-nine approved drugs.

There are three tentative approvals on CHARTWELL drugs.

Summary for Chartwell

US Patents:	0
Tradenames:	386
Ingredients:	362
NDAs:	579

Drugs and US Patents for Chartwell

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecules	GEMFIBROZIL	gemfibrozil	TABLET;ORAL	074270-001	Sep 27, 1993	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell	CIPROFLOXACIN HYDROCHLORIDE	ciprofloxacin hydrochloride	TABLET;ORAL	076896-002	Nov 4, 2004	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Rx	IRBESARTAN	irbesartan	TABLET;ORAL	203161-001	Sep 27, 2012		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Tetra	TETRACYCLINE HYDROCHLORIDE	tetracycline hydrochloride	CAPSULE;ORAL	062752-001	Aug 12, 1988	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Molecular	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	076890-003	Mar 30, 2012	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Rx	FLURAZEPAM HYDROCHLORIDE	flurazepam hydrochloride	CAPSULE;ORAL	071068-001	Nov 25, 1986		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Chartwell Rx	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF	cetirizine hydrochloride	SOLUTION;ORAL	090378-001	May 9, 2008		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-007	Approved Prior to Jan 1, 1982	3,491,093	⤷ Subscribe
Chartwell Molecular	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	⤷ Subscribe
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-006	Approved Prior to Jan 1, 1982	3,491,093	⤷ Subscribe
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-008	Approved Prior to Jan 1, 1982	3,491,093	⤷ Subscribe
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-005	Approved Prior to Jan 1, 1982	3,491,093	⤷ Subscribe
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-004	Approved Prior to Jan 1, 1982	3,491,093	⤷ Subscribe
Chartwell Rx	LIMBITROL	amitriptyline hydrochloride; chlordiazepoxide	TABLET;ORAL	016949-001	Approved Prior to Jan 1, 1982	4,316,897	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.